Analysts Set Invivyd, Inc. (NASDAQ:IVVD) PT at $7.33

Shares of Invivyd, Inc. (NASDAQ:IVVD) have been given an average rating of “Hold” by the seven brokerages that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $8.00.

Several research analysts have issued reports on the stock. Cantor Fitzgerald started coverage on shares of Invivyd in a report on Monday, October 6th. They set an “overweight” rating and a $10.00 target price on the stock. BTIG Research assumed coverage on shares of Invivyd in a research note on Monday, December 22nd. They set a “buy” rating and a $10.00 price objective on the stock. HC Wainwright lifted their price objective on shares of Invivyd from $5.00 to $10.00 and gave the company a “buy” rating in a report on Friday, October 31st. D Boral Capital lowered Invivyd from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 25th. Finally, D. Boral Capital reaffirmed a “hold” rating on shares of Invivyd in a research report on Tuesday, November 25th.

Insiders Place Their Bets

In related news, Director Kevin F. Mclaughlin bought 50,000 shares of the business’s stock in a transaction on Wednesday, November 19th. The shares were bought at an average price of $2.50 per share, for a total transaction of $125,000.00. Following the completion of the purchase, the director directly owned 50,000 shares of the company’s stock, valued at approximately $125,000. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 25.40% of the stock is currently owned by insiders.

Institutional Trading of Invivyd

A number of institutional investors have recently modified their holdings of the company. RA Capital Management L.P. purchased a new position in shares of Invivyd in the 3rd quarter worth approximately $18,831,000. ADAR1 Capital Management LLC purchased a new position in Invivyd in the third quarter worth $8,108,000. Vanguard Group Inc. increased its position in shares of Invivyd by 46.7% during the third quarter. Vanguard Group Inc. now owns 5,762,894 shares of the company’s stock worth $6,339,000 after purchasing an additional 1,834,970 shares in the last quarter. Boothbay Fund Management LLC acquired a new position in shares of Invivyd during the third quarter worth $894,000. Finally, AQR Capital Management LLC lifted its holdings in shares of Invivyd by 2,051.0% during the 1st quarter. AQR Capital Management LLC now owns 410,711 shares of the company’s stock valued at $249,000 after purchasing an additional 391,617 shares during the last quarter. 70.36% of the stock is currently owned by institutional investors.

Invivyd Stock Down 4.3%

Shares of NASDAQ:IVVD opened at $2.69 on Friday. The business’s 50 day moving average is $2.20 and its 200 day moving average is $1.40. The stock has a market cap of $627.09 million, a P/E ratio of -5.72 and a beta of 0.61. Invivyd has a 52-week low of $0.35 and a 52-week high of $3.07.

Invivyd (NASDAQ:IVVD) last issued its earnings results on Thursday, November 6th. The company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). Invivyd had a negative net margin of 119.63% and a negative return on equity of 92.97%. The firm had revenue of $13.13 million for the quarter, compared to the consensus estimate of $12.00 million. On average, sell-side analysts anticipate that Invivyd will post -1.64 EPS for the current fiscal year.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.